The Myeloma Trial Finder lists the clinical trials that are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.

Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone, please call the Myeloma Infoline on 0800 980 3332

Last update: 27/07/2023

There are currently 35 open trials. In 140 locations

What is a Clinical Trial?

Step 2: Choose a Trial

There are currently 35 open trials

Step 3: View Details

Trial Title:

SAR445514 for relapsed/refractory myeloma and relapsed/refractory AL amyloidosis



Myeloma stage:

Relapsed, Refractory, AL amyloidosis

Trial phase:




This trial is investigating the safety and effectiveness of SAR445514 for the treatment of relapsed and/or refractory myeloma or AL amyloidosis.



The Christie Hospital, Manchester;
University College Hospital, London

Who can enter the study?

Who can enter the study?:

Myeloma patients

Relapsed and/or refractory myeloma patients who have had at least two previous lines of treatment which included:

  • an immunomodulatory drug such as lenalidomide and,
  • a steroid such as dexamethasone and,
  • a proteosome inhibitor such as bortezomib and,
  • an anti-CD38 monoclonal antibody such as daratumumab

AL amyloidosis patients

Relapsed and/or refractory AL amyloidosis patients who have had at least one previous life of treatment which included:

  • a proteosome inhibitor such as bortezomib
What's involved?

What's involved?:

Patients will receive SAR445514 subcutaneously (an injection into the skin).

Different groups of patients will be given different doses of SAR445514 .

Patients will be required to attend outpatient clinics for regular check-ups and tests for at least 15 months.

Clinical Information

Clinical Information
(for Medical Professionals):

This is a phase 1/2, first-in-human, dose escalation trial of SAR445514, an NKcell Engager (NKCE) Targeting B-cell Maturation Antigen (BCMA) in Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and in Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

For more information, click here.


Find out more about Myeloma UK:


Do you want to talk to someone? Call our myeloma Infoline